CKD awareness gap leaves most GLP 1 kidney candidates undiagnosed

A national survey analysis puts a size on the CKD awareness gap that stands between GLP 1 drugs and the kidneys they could protect. About 9.1 million US adults with type 2 diabetes meet the criteria for the semaglutide kidney indication, yet 82.3 percent of them do not know they have chronic kidney disease, investigators reported at ASN Kidney Week 2026 in Denver. The share barely changed over a decade. No molecule moves on our board. The finding is about who reaches an approved drug, not about the drug itself.

Why semaglutide eligibility depends on a diagnosis

The kidney case for GLP 1 drugs rests largely on FLOW, a Novo Nordisk trial of 3,533 adults with type 2 diabetes and chronic kidney disease. In FLOW, weekly semaglutide cut the risk of major kidney disease events by 24 percent against placebo, and the FDA added a kidney indication in 2025. That label only helps people whose kidney disease has been found and named. Chronic kidney disease is quiet in its early stages, and the authors note that up to nine in ten affected US adults do not know they have it. Nobody had measured how many diabetes patients qualify for kidney protective GLP 1 treatment, or how many of them have been told they have kidney disease.

Ozioma Akahara of Houston Methodist Hospital and colleagues set out to fill that gap with the National Health and Nutrition Examination Survey, the long running federal survey that pairs interviews with laboratory tests. They pooled four survey cycles from 2013 to 2023, covering 21,450 adults. Chronic kidney disease was defined by laboratory values: an eGFR below 60, calculated with the 2021 race free CKD EPI equation, or a urine albumin to creatinine ratio of at least 30 milligrams per gram. Unawareness meant having laboratory evidence of the disease without ever being told by a clinician. Eligibility was judged two ways, under the FDA label with KDIGO guideline criteria, and under the stricter entry rules of the FLOW trial.

Sizing the CKD awareness gap in type 2 diabetes

Under the label and guideline criteria, the team estimated that 9.09 million US adults qualify, about 3.96 percent of the adult population, with a 95 percent confidence interval of 8.38 to 9.80 million. Of these candidates, 82.3 percent were unaware of their kidney disease, which works out to roughly 7.5 million people. Only 17.7 percent, about 1.6 million, said a clinician had ever told them they had kidney disease. The estimate rests on 1,177 unweighted survey participants, scaled up with the survey's national weights. That is a solid base for a national figure, though the confidence interval around the unaware share still runs from 79.1 to 85.6 percent.

Of these candidates, 82.3 percent were unaware of their kidney disease, which works out to roughly 7.5 million people.

The stricter FLOW criteria describe a smaller and sicker group, about 0.94 million adults, and the picture there is only a little better. Even in this group, 59.7 percent had never been told about their kidney disease, although that estimate rests on only 150 participants and its interval is wide. The table sets the two definitions side by side. For the board, the first row is the one that matters most. A drug can carry a kidney indication, but its reach is capped by how many patients have a diagnosis on file. Any growth in kidney protective GLP 1 use will depend as much on testing as on prescribing habits.

A decade without progress across subgroups

Across demographic groups, unawareness ranged from 79 to 89 percent. The highest rates were among non Hispanic Asian adults, at 89 percent, and adults younger than 65, at 86 percent. The investigators described this as a gap in how health systems detect and communicate kidney disease, not a problem limited to particular populations. The pattern over time points the same way. From 2013 to 2023 the number of eligible adults grew from about 8.2 million to 10.4 million, yet the unaware share held between roughly 80 and 85 percent in every survey cycle. More people qualified each year, and the same large share of them went undiagnosed.

The analysis has limits. It is a poster at a meeting, not a peer reviewed paper, so the full methods have not been through review. Survey data capture what people say a clinician told them, which may undercount some diagnoses that were made but not remembered. And meeting eligibility criteria does not mean every one of these patients would be offered or suited to the drug. The figures come from the poster as described by HCPLive's report from Kidney Week, and we have not seen the poster itself. Even so, the direction is clear, and it fits the authors' wider point that most US adults with kidney disease do not know it.

What closes the gap for GLP 1 kidney protection

The authors propose practical fixes. The first is to pair eGFR with a urine albumin test as routine, because eGFR alone misses kidney disease that shows up first as protein in the urine. They also call for building kidney screening into diabetes care, closer joint management between nephrology and primary care, and education aimed at the groups with the highest unawareness. Finally they suggest tracking awareness, treatment uptake and kidney outcomes over time, so progress can be measured. None of these steps involves a new molecule, but each would widen the pool of people who can benefit from GLP 1 kidney protection already on the label.

For a pipeline tracker, the result is a useful reminder that stage moves on their own are only half the story. Drugs reaching approval with kidney claims, and others such as retatrutide that are testing kidney endpoints now, will face the same diagnostic bottleneck. Our report on the retatrutide kidney trial shows how such endpoints are measured in a trial. The full roster of GLP 1 and related molecules sits on our incretins class page. The CKD awareness gap will shape how many people those molecules reach, and it is worth watching alongside the readouts that move them on the board.

Conclusion

The CKD awareness gap is large and stable: about 9.1 million US adults with type 2 diabetes qualify for kidney protective GLP 1 treatment, and more than four in five have not been told they have kidney disease. The data come from a meeting poster built on national survey records. The next checkpoint is whether routine albumin testing in diabetes care starts to move the unaware share. This story is research news, not medical advice.